Document Detail


Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
MedLine Citation:
PMID:  21077943     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To evaluate the effects of 1-year treatment with orlistat plus l-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and inflammatory parameters in obese type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA(1c) ) > 8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomized to take orlistat 120 mg three times a day plus l-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated the following parameters at baseline and after 3, 6, 9, and 12 months : body weight, body mass index (BMI), glycated hemoglobin (HbA(1c) ), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (Tg), adiponectin (ADN), leptin, tumor necrosis factor-α (TNF-α), vaspin, and high-sensitivity C-reactive protein (Hs-CRP). We observed a better decrease in body weight, glycemic profile, HOMA-IR, LDL-C, and ADN and a faster improvement in FPI, TC, Tg, leptin, TNF-α, Hs-CRP with orlistat plus l-carnitine compared to orlistat alone. We also recorded an improvement in vaspin with orlistat plus l-carnitine not reached with orlistat alone. Orlistat plus l-carnitine gave a better improvement in body weight, glycemic and lipid profile compared to orlistat alone; furthermore, a faster and better improvement in inflammatory parameters was observed with orlistat plus l-carnitine compared to orlistat alone.
Authors:
Giuseppe Derosa; Pamela Maffioli; Ilaria Ferrari; Angela D'Angelo; Elena Fogari; Ilaria Palumbo; Sabrina Randazzo; Arrigo F G Cicero
Related Documents :
15940383 - No evidence of insulin resistance in normal weight vegetarians. a case control study.
15947493 - Association between impaired insulin sensitivity and stroke.
15762193 - Defective glucose and lipid metabolism in human immunodeficiency virus-infected patient...
Publication Detail:
Type:  Journal Article     Date:  2010-11-16
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  25     ISSN:  1472-8206     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  642-51     Citation Subset:  IM    
Copyright Information:
© 2010 The Authors Fundamental and Clinical Pharmacology © 2010 Société Française de Pharmacologie et de Thérapeutique.
Affiliation:
Fondazione IRCCS Policlinico S. Matteo, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P.le C. Golgi, 2 - 27100 PAVIA, Italy "G. Descovich" Atherosclerosis Study Center, Department of Internal Medicine, Aging and Kidney diseases, University of Bologna, Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatic and renal toxicities of indomethacin acid, salt form and complexed forms with hydroxypropyl-...
Next Document:  Oral antiplatelet agents in ACS: from pharmacology to clinical differences.